ReviewPharmaceutics2021
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 69 citations in OpenAlex.
- X-ray crystal structures of the cannabinoid synthases CBCAS, CBDAS and THCAS.Current research in structural biology · 2026Article
- Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities.Biomolecules · 2026Review
- Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.Journal of cannabis research · 2026Article
- Review
- Sex differences in the disposition of cannabidiol and its metabolites in mice.Journal of cannabis research · 2026Article
- Cannabinoid efficacy for pain: dose, chronicity and route.Frontiers in neuroscience · 2026Review
- The potential of hemp roots, microgreens and leaves for human nutrition.Journal of cannabis research · 2025Article
- Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Self-Assembled Cannabigerol-Based Nanoparticles: Design, Synthesis, and Antiproliferative Activity.Pharmaceutics · 2025Article
- Article
- Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks.Biomedicines · 2025Review
- The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors.CNS drugs · 2025Review
- The Impact of Potent Addictive Substances on Angiogenic Behavior: A Comprehensive Review.Current neuropharmacology · 2025Review
- Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.Handbook of experimental pharmacology · 2025Review
- Cannabigerol Treatment Shows Antiproliferative Activity and Causes Apoptosis of Human Colorectal Cancer Cells.Journal of pharmacopuncture · 2024Article
- Article
- Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.Molecules (Basel, Switzerland) · 2024Review
- Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities.The Journal of pharmacology and experimental therapeutics · 2024Review
- Fatty Acid Amides Suppress Proliferation via Cannabinoid Receptors and Promote the Apoptosis of C6 Glioma Cells in Association with Akt Signaling Pathway Inhibition.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Charting the Cannabis plant chemical space with computational metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors. Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, transient receptor ankyrin 1 potential, peroxisome proliferator-activated receptor-gamma or glitazone receptor, G55 protein-coupled receptor, and nuclear receptor, producing pharmacological effects in diseases such as Alzheimer's, epilepsy, depression, neuropathic pain, cancer, and diabetes. Nonetheless, further studies are needed to elucidate the precise mechanisms of these compounds. Structure modulation of phytocannabinoids, in order to improve pharmacological effects, should not be limited to the exploration of cannabinoid receptors, and it should target other courses of action discovered through recent research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.